The Fort Worth Press - RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

USD -
AED 3.672504
AFN 66.379449
ALL 81.856268
AMD 381.470403
ANG 1.790403
AOA 917.000367
ARS 1450.931504
AUD 1.48876
AWG 1.80025
AZN 1.70397
BAM 1.658674
BBD 2.014358
BDT 122.21671
BGN 1.660404
BHD 0.377363
BIF 2957.76141
BMD 1
BND 1.284077
BOB 6.926234
BRL 5.544041
BSD 1.00014
BTN 89.856547
BWP 13.14687
BYN 2.919259
BYR 19600
BZD 2.011466
CAD 1.36805
CDF 2200.000362
CHF 0.789185
CLF 0.023092
CLP 905.903912
CNY 7.028504
CNH 7.004085
COP 3697
CRC 499.518715
CUC 1
CUP 26.5
CVE 93.513465
CZK 20.589604
DJF 177.720393
DKK 6.345404
DOP 62.690023
DZD 129.720387
EGP 47.553819
ERN 15
ETB 155.604932
EUR 0.849304
FJD 2.269204
FKP 0.741407
GBP 0.740741
GEL 2.68504
GGP 0.741407
GHS 11.126753
GIP 0.741407
GMD 74.503851
GNF 8741.153473
GTQ 7.662397
GYD 209.237241
HKD 7.77175
HNL 26.362545
HRK 6.400904
HTG 130.951927
HUF 328.603831
IDR 16772.3
ILS 3.19263
IMP 0.741407
INR 89.805304
IQD 1310.19773
IRR 42125.000352
ISK 125.730386
JEP 0.741407
JMD 159.532199
JOD 0.70904
JPY 156.57504
KES 128.950385
KGS 87.425039
KHR 4008.85391
KMF 418.00035
KPW 899.971411
KRW 1442.330383
KWD 0.30716
KYD 0.833489
KZT 514.029352
LAK 21644.588429
LBP 89561.205624
LKR 309.599834
LRD 177.018844
LSL 16.645168
LTL 2.95274
LVL 0.60489
LYD 5.412442
MAD 9.124909
MDL 16.777482
MGA 4573.672337
MKD 52.283113
MMK 2099.801262
MNT 3558.008545
MOP 8.011093
MRU 39.604456
MUR 45.990378
MVR 15.450378
MWK 1734.230032
MXN 17.910804
MYR 4.048504
MZN 63.910377
NAD 16.645168
NGN 1451.090377
NIO 36.806642
NOK 10.009404
NPR 143.770645
NZD 1.713209
OMR 0.384681
PAB 1.000136
PEN 3.365433
PGK 4.319268
PHP 58.710375
PKR 280.16122
PLN 3.58005
PYG 6777.849865
QAR 3.645469
RON 4.325104
RSD 99.70188
RUB 79.007431
RWF 1456.65485
SAR 3.750704
SBD 8.153391
SCR 14.464811
SDG 601.503676
SEK 9.157904
SGD 1.284104
SHP 0.750259
SLE 24.075038
SLL 20969.503664
SOS 570.585342
SRD 38.335504
STD 20697.981008
STN 20.777943
SVC 8.75133
SYP 11056.775561
SZL 16.631683
THB 31.070369
TJS 9.19119
TMT 3.51
TND 2.909675
TOP 2.40776
TRY 42.837504
TTD 6.803263
TWD 31.395038
TZS 2470.000335
UAH 42.191946
UGX 3610.273633
UYU 39.087976
UZS 12053.751267
VES 288.088835
VND 26291
VUV 120.676599
WST 2.77085
XAF 556.301203
XAG 0.012608
XAU 0.000221
XCD 2.70255
XCG 1.802508
XDR 0.692918
XOF 556.303562
XPF 101.141939
YER 238.450363
ZAR 16.668037
ZMK 9001.203584
ZMW 22.577472
ZWL 321.999592
  • VOD

    0.0200

    13.12

    +0.15%

  • NGG

    0.1500

    77.64

    +0.19%

  • BTI

    0.0300

    57.27

    +0.05%

  • RBGPF

    -0.5500

    80.71

    -0.68%

  • SCS

    0.0200

    16.14

    +0.12%

  • RIO

    1.3500

    82.24

    +1.64%

  • RYCEF

    0.0300

    15.56

    +0.19%

  • CMSC

    0.0700

    23.09

    +0.3%

  • AZN

    0.4500

    92.9

    +0.48%

  • BP

    -0.0400

    34.27

    -0.12%

  • GSK

    0.1200

    49.08

    +0.24%

  • BCC

    0.4200

    75.13

    +0.56%

  • RELX

    0.0200

    41.11

    +0.05%

  • CMSD

    -0.0300

    23.11

    -0.13%

  • JRI

    0.0000

    13.47

    0%

  • BCE

    0.0400

    23.05

    +0.17%

RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today congratulated its former client, Cidara Therapeutics, on its acquisition by Merck for approximately $9.2 billion.

Text size:

RedChip began introducing Cidara to its global microcap and small-cap investor network in 2021, when the company's market capitalization was under $100 million and its groundbreaking antiviral and antifungal programs were still largely undiscovered by the broader investment community.

"Cidara's journey from a sub-$100 million emerging growth story to a multibillion-dollar strategic acquisition by Merck is exactly the type of transformational outcome RedChip seeks to spotlight for investors," said Dave Gentry, CEO of RedChip Companies. "We were proud to share the Cidara story at a time when its innovative Cloudbreak® platform and long-acting antiviral programs were just beginning to attract institutional attention. Seeing that early science culminate in one of the largest biotech acquisitions of the year validates both Cidara's vision and the importance of bringing promising small-cap opportunities to investors early."

As detailed in Merck's announcement, the acquisition centers on CD388, Cidara's investigational long-acting, strain-agnostic antiviral designed to prevent influenza infection in individuals at high risk of complications. CD388, now in Phase 3 development, was granted Breakthrough Therapy Designation by the FDA and is viewed as a potentially first-in-class seasonal prevention solution with global commercial potential.

"Cidara exemplifies the type of emerging blue-chip story that aligns with RedChip's 33-year mission," Gentry added. "We congratulate the Cidara team on this extraordinary milestone and look forward to continuing our work discovering tomorrow's leading innovators today."

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 33 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

To learn more about RedChip's products and services, please visit: https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
[email protected]

--END--

SOURCE: RedChip Companies, Inc.



View the original press release on ACCESS Newswire

S.Jones--TFWP